<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7380217\results\search\testTrace\results.xml">
  <result pre="without major complications, in a minority of the patients, the" exact="infection" post="leads to a life-threatening clinical situation involving any organ"/>
  <result pre="[6]. Whether the incidence of the severe syndrome of COVID-19" exact="infection" post="is diminished or enhanced in patients post-HCT relative to"/>
  <result pre="populations, and what risk factors are predictive of lower respiratory" exact="infection" post="and infection severity, are unclear at present. In addition,"/>
  <result pre="what risk factors are predictive of lower respiratory infection and" exact="infection" post="severity, are unclear at present. In addition, many donor"/>
  <result pre="arisen as a consequence of global lockdown, travel restrictions, and" exact="quarantine" post="procedures in various countries. Finally, many drugs currently used"/>
  <result pre="addition, blood loss prevention strategies (eg, minimizing blood draws or" exact="treatment" post="with tranexamic acid if clinically permissible) should be maximized"/>
  <result pre="care of them. At the same time, the risk of" exact="infection" post="from these visits must be considered, including such factors"/>
  <result pre="and an antibody-based test to detect the occurrence of previous" exact="infection" post="(which can take 1 to 3 weeks after infection"/>
  <result pre="previous infection (which can take 1 to 3 weeks after" exact="infection" post="to become positive). Notably, PCR-based testing does not distinguish"/>
  <result pre="to 3 weeks after infection to become positive). Notably, PCR-based" exact="testing" post="does not distinguish between live and dead SARS-CoV-2. For"/>
  <result pre="not distinguish between live and dead SARS-CoV-2. For diagnosing COVID-19" exact="infection" post="in HCT recipients, testing with real-time RT-PCR ideally should"/>
  <result pre="and dead SARS-CoV-2. For diagnosing COVID-19 infection in HCT recipients," exact="testing" post="with real-time RT-PCR ideally should be done on nasopharyngeal"/>
  <result pre="test being used, which may be affected by the regional" exact="prevalence" post="of the infection. Pitfalls in SARS-CoV-2 PCR diagnostics have"/>
  <result pre="At present, there is no known role for antibody-based (serologic)" exact="testing" post="for SARS-CoV-2 for diagnostic purposes. Exposure (especially to contacts"/>
  <result pre="helpful in evaluating HCT recipients. In the event that the" exact="diagnosis" post="is not clear, bronchoscopy with bronchoalveolar lavage may be"/>
  <result pre="of acquiring the SARS-CoV-2 infection. Specific symptoms/findings ascribed to SARS-CoV-2" exact="infection" post="including fever, chills, cough, shortness of breath or difficulty"/>
  <result pre="and lactate dehydrogenase levels, may help assess the severity of" exact="infection" post="and optimally should be performed in every patient with"/>
  <result pre="and tocilizumab in China. Ongoing clinical trials are examining various" exact="treatment" post="protocols. At present, there are no regulatory agencyâ€&quot;approved therapies"/>
  <result pre="there are no regulatory agencyâ€&quot;approved therapies or vaccines for the" exact="treatment" post="or prevention of COVID-19. Hydroxychloroquine, alone or in combination"/>
  <result pre="moderate/minimal impact on clinical outcomes [35]. Approved in China for" exact="treatment" post="of COVID-19 complications [36]. Used for the treatment of"/>
  <result pre="China for treatment of COVID-19 complications [36]. Used for the" exact="treatment" post="of acute GVHD. Reactivation of hepatitis B, hepatotoxicity, and"/>
  <result pre="or anti-IL6 receptor antibody therapy [28,37]. Also used for the" exact="treatment" post="of cytokine release syndrome after CAR T cell therapy."/>
  <result pre="hydroxychloroquine on the COVID-19 viral load [41]. Used as a" exact="treatment" post="for lung GVHD (BOS). Can cause QTc prolongation, torsades"/>
  <result pre="its association with a serious increase in the risk of" exact="infection" post="(meningococcus), use only in clinical trials. Siltuximab An improvement"/>
  <result pre="their condition [43]. Approved by the EMA and FDA for" exact="treatment" post="of adults with HHV6-/HIV- multicentric Castleman's disease Use only"/>
  <result pre="hemophagocytic lymphohistiocytosis due to COVID-19 (trials started) Approved for the" exact="treatment" post="of steroid-refractory acute GVHD. Risk of infection and thrombocytopenia"/>
  <result pre="Approved for the treatment of steroid-refractory acute GVHD. Risk of" exact="infection" post="and thrombocytopenia with full-dose ruxolitinib. Thrombocytopenia and an ITP-like"/>
  <result pre="already on ibrutinib. Caution against using ibrutinib solely for COVID-19" exact="infection" post="in HCT recipients until trial data available Immunosuppressives Corticosteroids"/>
  <result pre="shown to improve mortality in COVID-19 patients [53]. The primary" exact="treatment" post="for both acute and chronic GVHD. Judicious use of"/>
  <result pre="outcome in a single-arm trial of 7 patients [56]. Approved" exact="treatment" post="for acute GVHD in Canada, New Zealand, and Japan"/>
  <result pre="of ALL and NHL. Post-CAR T cell infusion, any drug" exact="treatment" post="should strictly be in the context of clinical trials."/>
  <result pre="increasing ACE2 expression (virus-binding site) [57,58]. No known role for" exact="treatment" post="of any aspect of HCT. Until data are available,"/>
  <result pre="trial demonstrated arbidol monotherapy had little benefit for mild/moderate COVID-19" exact="infection" post="[59]. No definite role specifically in HCT. Adverse events"/>
  <result pre="personnel to exposure (necessitating quarantine) or infection. Strict adherence to" exact="infection" post="control measures is imperative to minimize the transmission of"/>
  <result pre="as patients exposed to persons with active upper respiratory tract" exact="infection" post="symptoms, then a second RT-PCR analysis is advisable even"/>
  <result pre="should attempt to reduce the risk of exposure by home" exact="isolation" post="for at least 14 days before starting conditioning. If"/>
  <result pre="postponed owing to concerns about intensive care unit capacity or" exact="infection" post="prevalence, it is imperative to complete the proper risk"/>
  <result pre="be individualized, weighing the risks for serious complications from COVID-19" exact="infection" post="against the risks of disease progression if HCT is"/>
  <result pre="general, using peripheral blood stem cells (PBSCs) with cryopreservation and" exact="testing" post="the quality of thawed product before the start of"/>
  <result pre="American Association of Blood Banks guidelines do not recommend universal" exact="screening" post="for SARS-CoV-2 in blood products, and current FDA guidelines"/>
  <result pre="blood products, and current FDA guidelines recommend considering the donor's" exact="infection" post="and exposure history in the 28 days before donation"/>
  <result pre="Marrow Donor Program/Be The Match has already implemented a donor" exact="screening" post="questionnaire [27]. The World Marrow Donor Association has also"/>
  <result pre="of patients infected with COVID-19 who are undergoing HCT, the" exact="treatment" post="paradigm should follow the institutional policies. In general, if"/>
  <result pre="should be delayed until the patient completely recovers from the" exact="infection" post="(at least 14 days). Two consecutive negative RT-PCR analyses"/>
  <result pre="should continue owing to anticipated bone marrow aplasia. The COVID-19" exact="infection" post="should be managed symptomatically or on a clinical trial"/>
  <result pre="clinical trial with a cautious evaluation of drug-drug interactions. If" exact="infection" post="with COVID-19 is diagnosed on the day of transplantation"/>
  <result pre="bone marrow infusion. Convalescent plasma infusions, if indicated for COVID-19" exact="infection" post="on a clinical trial, should be avoided on the"/>
  <result pre="to minimize the risk of allergic reactions. If the COVID-19" exact="infection" post="is diagnosed after the stem cell infusion, then it"/>
  <result pre="multidisciplinary team for an individualized decision. HOSPITALIZATION AND TRANSPLANTATION Special" exact="infection" post="control measures, including strict use of proper personal protective"/>
  <result pre="wait for results if possible. HCT recipients with confirmed COVID-19" exact="infection" post="should not stay in a positive-pressure room and must"/>
  <result pre="infections and organ damage from COVID-19. The usual recommendations for" exact="infection" post="prevention, including maintaining strict hand hygiene, wearing surgical or"/>
  <result pre="available, with checkpoints at the entrance.Â Patients with confirmed COVID-19" exact="infection" post="should be tested regularly (depending on the institutional policies"/>
  <result pre="be considered potentially infectious. Other important issues to address include" exact="social distancing" post="and mask wearing in the waiting area, direct rooming"/>
  <result pre="management guidelines. This has practical implications for vaccinations and COVID-19" exact="treatment" post="strategies. If possible, these patients should be cared for"/>
  <result pre="if available. Of note, the role of convalescent plasma for" exact="treatment" post="of COVID-19 has not been proven in the allogeneic"/>
  <result pre="currently residing in a country/state/province/city that has an extremely high" exact="prevalence" post="of SARS-CoV-2. HCT recipients who will require frequent visits"/>
  <result pre="as prevention of nosocomial transmission, protection of HCT staff, and" exact="treatment" post="of COVID-19 in HCT recipients. The extreme changeability of"/>
  <result pre="review on the efficacy and safety of chloroquine for the" exact="treatment" post="of COVID-19J Crit Care57202027928332173110 19ZhangLZhuFXieLClinical characteristics of COVID-19-infected cancer"/>
  <result pre="zoonotic coronavirusesSci Transl Med92017eaal3653 32de WitEFeldmannFCroninJProphylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
  <result pre="with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialLancet39520201569157832423584 35XuXHanMLiTEffective" exact="treatment" post="of severe COVID-19 patients with tocilizumabChinaXiv2020202003.00026v1 36Liu R, Miller"/>
  <result pre="COVID-19 patients: a pilot studymedRxiv202003.16.20036145 41GautretPLagierJCParolaPHydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
  <result pre="in hospitalized patients with Covid-19N Engl J Med38220202411241832379955 45RosenbergESDufortEMUdoTAssociation of" exact="treatment" post="with hydroxychloroquine or azithromycin with in-hospital mortality in patients"/>
  <result pre="RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysis. Lancet. 5-22-2020. doi:"/>
  <result pre="novel coronavirus (COVID-19): molecular docking studymedRxiv2020202004.0079.v1 51Diurno FNumis FGPorta GEculizumab" exact="treatment" post="in patients with COVID-19: preliminary results from real life"/>
  <result pre="dose-response meta-analysisOsteoporos Int2820171027103427844132 55WangYJiangWHeQEarly, low-dose and short-term application of corticosteroid" exact="treatment" post="in patients with severe COVID-19 pneumonia: single-center experience from"/>
 </snippets>
</snippetsTree>
